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Abstract
Purpose Cabozantinib (XL184), a multi-targeted oral tyr-
osine kinase inhibitor with activity against MET, VEGFR2,
AXL, and other tyrosine kinases, was assessed in a cohort
of metastatic breast cancer (MBC) patients in a phase II
randomized discontinuation trial (RDT).
Methods Patients received 100 mg cabozantinib daily
during a 12-week lead-in stage. Those with stable disease
per modified Response Evaluation Criteria in Solid Tumors
version 1.0 at 12 weeks were randomized to either continue
cabozantinib or receive placebo. Primary endpoints were
objective response rate (ORR) during the 12-week lead-in
stage and progression-free survival (PFS) after
randomization. Patients were also followed for overall
survival (OS).
Results Forty-five patients with MBC and a median of
three prior lines of chemotherapy for metastatic disease
were enrolled. The ORR during the lead-in stage was
13.6 % (95 % confidence interval [CI] 6–25.7 %), and the
disease control rate at week 12 was 46.7 % (95 % CI
31.7–61.6 %). Per the initial RDT study design, patients
with stable disease at week 12 were randomized to
cabozantinib or placebo. Following a Study Oversight
Committee recommendation, randomization was sus-
pended. Patients in the lead-in stage continued on open-
label cabozantinib. Patients in the randomization stage
were subsequently unblinded. The overall median PFS for
all MBC patients was 4.3 months. Median OS was
11.4 months (95 % CI 10.5–16.5 months). The most
common grade 3/4 adverse events in the lead-in stage were
palmar-plantar erythrodysesthesia (13 %) and fatigue
(11 %). One death from respiratory failure was reported as
drug-related during the lead-in stage.
Conclusions In heavily pretreated MBC patients,
cabozantinib monotherapy demonstrated clinical activity
including objective response and disease control.
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Introduction
Cabozantinib is an orally bioavailable tyrosine kinase
inhibitor with potent activity against MET, vascular
endothelial growth factor receptor-2 (VEGFR2), AXL, and
other receptor tyrosine kinases (RTKs) that have also been
implicated in tumor pathobiology, including RET, KIT,
and FLT3 [1]. In vivo, cabozantinib suppresses MET and
VEGFR2 signaling, rapidly inducing endothelial and tumor
cell apoptosis, resulting in tumor regression in various
xenograft models [1].
MET and its ligand hepatocyte growth factor (HGF)
have been implicated in diverse aspects of tumor pathobi-
ology, including tumor growth, survival, angiogenesis,
invasion, and dissemination [2]. Molecular alterations
directly affecting MET are relatively rare in breast cancer
(BC). For example, molecular inversion probe arrays of
971 early BCs revealed that 8 % exhibited an elevation of
c-Met copy number [3]. However, MET pathway activation
and dysregulation are implicated via other mechanisms in
BC pathobiology. MET and HGF expression is signifi-
cantly higher in BC cells than in adjacent non-tumor cells
in surgical specimens [4]. High tumor MET expression was
evident in 89 of 170 (52 %) patients with triple-negative
BC and predicted shorter survival [5]. In tumor tissue from
node-positive BC patients, MET overexpression was
associated with poor clinical outcome independent of
human epidermal growth factor receptor-2 (HER2) status
[6]. Elevated levels of circulating HGF are also common
and are an independent prognostic indicator associated
with worse outcome in primary BC patients [7].
The VEGF receptors and ligands are central mediators
of tumor neoangiogenesis and lymphangiogenesis [8].
High tumor microvessel density is predictive of poor
relapse-free and overall survival (OS) in BC [9]. Moreover,
elevated VEGF expression is associated with decreased
relapse-free and OS in early stage BC [10, 11]. Beva-
cizumab, an anti-VEGF monoclonal antibody, was initially
authorized by the United States Food and Drug Adminis-
tration (FDA) for use in combination with chemotherapy as
first-line therapy for metastatic breast cancer (MBC) based
on significantly improved progression-free survival (PFS)
demonstrated in several studies [12, 13]. However, the
substantial PFS benefit with bevacizumab did not translate
into prolonged OS, and the BC indication was later with-
drawn in the United States. It is now evident that inhibition
of VEGF signaling alone, although initially effective in
slowing tumor growth, often culminates in emergence of an
evasive resistance phenotype that ultimately promotes
tumor invasiveness and metastasis [14]. MET has been
implicated in such resistance in multiple preclinical mod-
els, and, in a pancreatic neuroendocrine tumor model,
combined inhibition of VEGFR and MET results in
enhanced efficacy over inhibition of either pathway alone
[15–18].
Based on the broad preclinical and clinical activities of
cabozantinib, a phase II randomized discontinuation trial
(RDT) was conducted in nine selected tumor types: MBC,
castration-resistant prostate cancer, hepatocellular carci-
noma, non-small cell lung cancer, ovarian cancer, mela-
noma, pancreatic cancer, small cell lung cancer, and
gastric/gastroesophageal junction cancer (ClinicalTrials.-
gov NCT00940225) [19, 20]. We herein describe the
results for the cohort of patients with MBC.
Patients and methods
Patients
Eligible patients had MBC that was estrogen receptor-
positive (ER?), ER/progesterone receptor (PgR)/HER2-
negative (triple-negative), or inflammatory (regardless of
receptor status) with measurable disease by modified
Response Evaluation Criteria in Solid Tumors version 1.0
(mRECIST) and evidence of progression on computed
tomography (CT), magnetic resonance imaging (MRI), or
bone scan at screening. Additional inclusion criteria were
Eastern Cooperative Oncology Group performance status
(ECOG PS) 0 or 1, adequate hematologic and end-organ
function, and no more than four prior standard
chemotherapy regimens completed C4 weeks before study
entry. Patients must have discontinued fulves-
trant C4 weeks prior and other endocrine
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therapy C2 weeks prior to first dose of study drug. Patients
with active brain metastases, radiation therapy within
2 weeks, or clinically significant intercurrent illness were
excluded. The study was conducted in accordance with the
Declaration of Helsinki and Good Clinical Practice
guidelines. The study protocol and informed consent doc-
uments were reviewed and approved by the participating
institutions’ Institutional Review Boards, and all patients
provided consent before any study-specified procedures.
Study design
The primary objective was to evaluate the antitumor
activity of cabozantinib in multiple solid tumors including
MBC. The primary endpoints were objective response rate
(ORR) during the 12-week lead-in stage and progression-
free survival (PFS) post-randomization. Secondary objec-
tives assessed the safety and tolerability of the agent and
potential pharmacodynamic effects. The study was
designed as a randomized discontinuation trial (RDT)
(Fig. 1). Patients received cabozantinib at a daily oral dose
of 100 mg (freebase weight) during a 12-week, open-label,
lead-in stage. Cabozantinib dosing was delayed or the daily
dose reduced if clinically significant toxicities developed.
Dosing interruption for B6 weeks was allowed.
Laboratory tests for safety monitoring were performed
every 2 weeks through week 12, then every 3 weeks.
Tumors were assessed every 6 weeks throughout the study.
At week 12, patients with evidence of response by mRE-
CIST remained on open-label cabozantinib, and patients
with progression discontinued. Patients with stable disease
at week 12 were randomized to either continued cabozan-
tinib or placebo in double-blinded fashion. All randomized
patients were followed until progression, at which point
treatment assignment was unblinded, patients receiving
cabozantinib were discontinued, and patients receiving
placebo were allowed to restart cabozantinib and were then
followed until subsequent progression. The protocol was
amended to add follow-up for OS.
Study assessments
Efficacy assessments included radiographic soft tissue and
bone imaging. After enrollment of the first 20 patients, a
protocol amendment required bone scans at baseline and
follow-up assessments for patients with known bone
metastases. The PFS analysis was conducted based on
investigator-assessed response by mRECIST.
Other clinical assessments included medical and cancer
history, physical examination, vital signs and body weight,
electrocardiography, ECOG PS, safety laboratory values
(serum chemistry, hematology, coagulation, urinalysis),
concomitant medications, adverse events (AEs), and
information on subsequent anticancer treatment.
Study oversight
A Study Oversight Committee (SOC) monitored efficacy
during the lead-in stage. An independent data monitoring
committee monitored safety during the blinded randomized
stage.
Statistical considerations
The adaptive design study assumed that a stable disease
rate of 35 % in a cohort at week 12 would be of interest.
Up to 200 patients could be enrolled to a tumor-type cohort
to randomize 70 patients and achieve 52 events post-ran-
domization. This design had an 80 % power to detect a
hazard ratio of 0.5 for PFS post-randomization. Cohort
enrollment could be halted by the SOC if an insufficient
number of patients had disease stabilization because of
either high or low rates of clinical activity during the lead-
in stage. The SOC generally evaluated efficacy in incre-
ments of 20 patients, but their evaluations were not based
on patient completion of week 12.
The Kaplan–Meier method estimated medians for the
analysis of PFS from date of randomization and OS from
date of first dose. The estimation method described by
Ratain et al. [21] was used for the analysis of overall PFS
Lead-in stage
Cabozantinib
open-label
(100 mg)
Open-label extension
cabozantinib
Metastatic 
breast cancer
· ER+
· Triple–
· Invasive
Week 12
tumor
staging
Unblind at
disease progression
SD
PD
PR or CR
Discontinue
Placebo patients
may cross over
to cabozantinib
Discontinue
study treatment
Blinded randomized stage
cabozantinib vs. placebo
(1:1)
Fig. 1 Schematic of randomized discontinuation trial (RDT) design. ER estrogen receptor, CR complete response, PD progressive disease, PR
partial response, SD stable disease
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from the date of first dose, including the lead-in stage. All
treated patients contributed to the PFS estimate through
12 weeks; thereafter, the PFS was estimated as a weighted
average of those continuing on open-label treatment and
those randomized to cabozantinib. The weights corre-
sponded to the fraction of patients continuing on open-label
treatment at week 12 and the proportion of patients ran-
domized at week 12 (including patients randomized to
placebo).
Results
Patients and treatment
From November 2009 until October 2011, 45 patients with
MBC were enrolled in the United States, Belgium, and
Israel. Median follow-up was 14 months. Table 1 sum-
marizes baseline demographic and clinical characteristics.
Forty-three patients (96 %) were ER?, and two patients
were triple-negative. Lung, liver, and bone metastases were
present at baseline in 18 (40 %), 28 (62.2 %), and 33
(73 %) patients, respectively. Patients were heavily pre-
treated: 93 % with hormonal therapy, 53 % with three or
more lines of chemotherapy, 80 % with taxanes, 71 % with
anthracyclines, and 42 % with bevacizumab (Table 1). The
SOC recommended suspension of enrollment and ran-
domization of the MBC cohort after clinically significant
efficacy was observed in multiple tumor-type cohorts (in
the overall RDT), including MBC, due to the high disease
control rate (DCR) and rapid symptomatic progression of
many patients after randomization to placebo at week 12.
Before this decision, 10 patients with stable disease at
week 12 were randomized to either cabozantinib or pla-
cebo. Eleven patients continued open-label cabozantinib
after week 12 (Fig. 2). Twenty-four (53 %) patients dis-
continued study treatment during the lead-in stage (B12
weeks); five of these discontinued because of an AE.
Tumor response in the 12-week lead-in stage
The ORR per mRECIST during the 12-week lead-in stage
was 13.6 % (95 % CI 6–25.7 %); six patients achieved
confirmed partial response. The DCR, defined as the inci-
dence of partial response or stable disease at week 12, was
46.7 % (95 % CI 31.7–61.6 %). Twenty-five patients had
stable disease and nine patients had progressive disease as
their best overall response. Five patients were not evaluable
for response because baseline or post-baseline assessments
were unavailable. Reduction of target lesions as a best
overall response was documented for 64 % (25/39) of
evaluable patients (Fig. 3).
Progression-free and overall survival
Before suspension of randomization in the MBC cohort, 10
patients who had stable disease at week 12 were random-
ized (five cabozantinib, five placebo). Due to the small
sample size, the estimated PFS post-randomization is not
reported. The estimated median overall PFS for all patients
from study initiation was 4.3 months (Fig. 4a) [21]. Med-
ian OS was 11.4 months (Fig. 4b) [21].
Safety
Table 2 summarizes AEs reported during the lead-in stage
of the study regardless of attribution. All patients had at
least one AE, and most experienced more than one event.
The most common grade C3 events were palmar-plantar
erythrodysesthesia (PPE), fatigue, hypertension, abdominal
pain, asthenia, dyspnea, and increased aspartate amino-
transferase. One related grade 5 event of respiratory failure
was reported in a patient who progressed with multiple
Table 1 Baseline demographic and clinical characteristics of patients
(N = 45)
n %
Age, years
Median 56
Range 27–74
Receptor status
ER?/HER2- 35 78
ER?/HER2? 7 16
ER?/HER2 unknown 1 2
Triple-negative 2 4
Histologic subtype
Invasive ductal 37 82
Invasive lobular 3 7
Other 5 11
Visceral metastases
Lung metastases 18 40
Liver metastases 28 62
Bone metastases 33 73
Prior hormonal therapy 42 93
Prior lines of chemotherapy
0 1 2
1 4 9
2 16 36
C3 24 53
Prior taxane therapy 36 80
Prior anthracycline therapy 32 71
Prior bevacizumab 19 42
ER estrogen receptor, HER2 human epidermal growth factor receptor-
2, VEGF vascular endothelial growth factor
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pleural effusions that tested positive for malignant cells and
small pulmonary nodules suspicious for metastatic disease.
During the 12-week lead-in stage, five patients (11 %)
discontinued treatment because of an AE (Fig. 3), and
18 (40 %) had at least one dose reduction for any reason
other than patient error or noncompliance.
Discussion
In this phase II RDT, cabozantinib demonstrated clinical
activity in a heavily pretreated cohort of 45 MBC patients,
with an ORR of 13.6 % and week 12 DCR of 46.7 %. Most
patients had ER? disease (96 %) and a median of three
Patients enrolled
N = 45
Treatment discontinued
n = 24
Open-label cabozantinib
(100 mg)
Open-label continuation
n = 11
Placebo
n = 5
Cabozantinib
n = 5
End of Week 12
Randomization
(stable disease)
n = 10
Partial response: n = 6
Stable disease: n = 5b
Disease progression: n = 14
Adverse event: n = 5
Other: n = 2
Death: n = 3a
Fig. 2 CONSORT diagram: disposition of enrolled metastatic breast
cancer patients. aTwo deaths were disease progression, and the third
death was reported as respiratory compromise. bPatients with
stable disease at week 12 continued on open-label cabozantinib after
randomization was suspended upon recommendation of the indepen-
dent study oversight committee
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(N = 45)Fig. 3 a Summary of modified
RECIST version 1.0
(mRECIST) response. All
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the sum of patients with
confirmed partial response or
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b Best change from baseline in
investigator-assessed
measurements of soft-tissue
lesions using mRECIST was
determined for patients who had
baseline and at least one post-
baseline radiographic scan in
the first 12 weeks (n = 39).
aConfirmed partial response.
RECIST, Response Evaluation
Criteria in Solid Tumors
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prior lines of chemotherapy. Of the six patients with con-
firmed responses, five had ER?, HER2- breast cancer, and
one patient had ER?, HER2? disease.
Multiple RTKIs are in development for the treatment of
BC, but many of them have failed to demonstrate single-
agent efficacy. The success of these RTKIs may have been
hindered by the dependence of the malignancy on multiple
molecular pathways and by activation of compensatory
mechanisms. Antiangiogenic therapy for BC has gone
through a reversal with the FDA withdrawal of approval
for bevacizumab in this indication. However, combining
anti-VEGF pathway therapy with MET inhibition may help
overcome some of the resistance and escape mechanisms
that develop during treatment with anti-VEGF pathway
therapy alone. In particular, inhibition of MET may sup-
press the induction of MET-dependent tumor invasiveness
associated with VEGF blockade [14, 22]. Therefore, the
ability of cabozantinib to target multiple RTKs implicated
in cancer pathobiology, including MET and VEGFR2,
represents a potential advantage over agents directed
against VEGFR2 alone.
Clinical trials have examined the efficacy of a MET
inhibitor in combination with antiangiogenic therapy in
patients with triple-negative BC and, interestingly, the
addition of onartuzumab to either paclitaxel and beva-
cizumab or paclitaxel alone did not improve PFS or OS
compared with paclitaxel and bevacizumab; furthermore,
the efficacy in the MET-positive and MET-negative sub-
groups was similar [23]. Additionally, a study that examined
the MET tyrosine kinase inhibitor tivantinib in patients with
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Fig. 4 a Estimated overall progression-free survival for 45 metastatic
breast cancer patients, determined as described by Ratain et al. [21].
b Overall survival (26 death events and 19 patients censored). aSee
‘‘Patients and Methods’’ section for details on the PFS calculations
Table 2 Most frequently reported adverse events during lead-in
stage regardless of causality (N = 45)
Adverse eventb All grades Grade C3a
n % n %
Fatigue 32 71 5 11
Nausea 29 64 1 2
Diarrhea 25 56 2 4
PPE 20 44 6 13
Decreased appetite 20 44 1 2
Vomiting 17 38 1 2
Constipation 13 29 2 4
Hypertension 11 24 3 7
Decreased weight 11 24 2 4
Dysgeusia 11 24 – –
Dysphonia 11 24 – –
Abdominal pain 10 22 3 7
Asthenia 10 22 3 7
Headache 10 22 – –
Dyspnea 9 20 3 7
Dizziness 8 18 – –
Hypothyroidism 8 18 – –
Mucosal inflammation 8 18 – –
Back pain 7 16 2 4
Leukopenia 7 16 1 2
Stomatitis 7 16 1 2
Pain in extremities 7 16 – –
Pain 6 13 2 4
Alopecia 6 13 – –
Dyspepsia 6 13 – –
Rash 6 13 – –
Urinary tract infection 6 13 – –
Increased AST 5 11 3 7
Thrombocytopenia 5 11 1 2
Dry mouth 5 11 – –
Hair color changes 5 11 – –
Neutropenia 5 11 – –
Oral pain 5 11 – –
AST aspartate aminotransferase, PPE palmar-plantar
erythrodysesthesia
a One related grade 5 event was reported: respiratory compromise
b MedDRA v. 14.1 Preferred Terms (converted to US spelling),
CTCAE v. 3.0 grading
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metastatic triple-negative BC failed to demonstrate signifi-
cant activity as monotherapy [24]. However, both of these
studies of MET inhibition were conducted in patients with
triple-negative disease; in contrast, our study predominantly
enrolled patients with HR? BC.
In summary, the clinical activity of cabozantinib observed
in this first study of patients with heavily pretreated MBC is
encouraging and supports further testing of cabozantinib in
BC. Cabozantinib is currently FDA approved for metastatic
medullary thyroid cancer and renal cell carcinoma, and
studies are ongoing to further assess this agent in MBC.
These studies include an assessment of cabozantinib alone
and in combination with fulvestrant in patients with meta-
static HR? disease and known bone metastases (Clini-
calTrials.gov NCT01441947), a study of cabozantinib
monotherapy in patients with triple-negative MBC (Clini-
calTrials.gov NCT01738438), and a study of cabozantinib
(with trastuzumab for HER2? disease) in BC patients with
brain metastasis (ClinicalTrials.gov NCT02260531).
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